With Ph3 da­ta, Pfiz­er wants to have the ‘first and on­ly’ RSV vac­cine to cov­er adults as young as 18 years old

The race for RSV vac­cine mar­ket dom­i­nance con­tin­ues with Pfiz­er re­port­ing on Tues­day that Abrys­vo passed its reg­is­tra­tional test in at-risk peo­ple aged 18 to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER